• Policy
• Will Enhertu be reimbursed using flexible ICER threshold?
• by Lee, Tak-Sun Dec 14, 2023 05:47am

• Policy
• Only CKD and Jeil have high-dose Xeljanz generics approved
• by Lee, Hye-Kyung Dec 13, 2023 05:38am

• Policy
• KIDS ‘Oral VEGFR-TKI use may increase risk of AAD’
• by Lee, Hye-Kyung Dec 12, 2023 05:38am

• Policy
• MOHW agrees to review current prior authorization system
• by Lee, Jeong-Hwan Dec 12, 2023 05:38am

• Policy
• Roche’s DLBCL treatment Columvi approved in Korea
• by Lee, Hye-Kyung Dec 11, 2023 05:02am

• Policy
• Pfizer conducts trial for its RSV drug sisunatovir in KOR
• by Lee, Hye-Kyung Dec 11, 2023 05:02am

• Policy
• First Depakote generic is being reviewed for reimb in KOR
• by Lee, Tak-Sun Dec 8, 2023 05:55am

• Policy
• HIRA’s reimb reevaluation results to be released on the 7th
• by Lee, Tak-Sun Dec 7, 2023 05:47am

• Policy
• Bill proposed to prioritize domestic drugs and vaccines
• by Lee, Jeong-Hwan Dec 6, 2023 06:00am

• Policy
• New price adj guidelines set for drugs with unstable supply
• by Lee, Tak-Sun Dec 6, 2023 06:00am